Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

BCTX

BriaCell Therapeutics Corp

Nov 14 • 04:00PM ET

9.16

-0.57 -5.90 %

Healthcare • Biotechnology • Canada • NASD

Peers: GILD PBYI JNJ EXEL BMY MRK BLUE AZN FOLD AMGN

Index	-	P/E	-	EPS (ttm)	-76.67	Insider Own	5.09%	Shs Outstand	1.88M	Perf Week	-18.97%
Market Cap	17.23M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	1.79M	Perf Month	-25.61%
Enterprise Value	-1.19M	PEG	-	EPS next Q	-	Inst Own	9.83%	Short Float	7.22%	Perf Quarter	20.12%
Income	-26.31M	P/S	-	EPS this Y	-	Inst Trans	8.83%	Short Ratio	1.64	Perf Half Y	-68.83%
Sales	0.00M	P/B	0.97	EPS next Y	-	ROA	-191.21%	Short Interest	0.13M	Perf YTD	-89.19%
Book/sh	9.49	P/C	0.96	EPS next 5Y	-	ROE	-339.54%	52W High	190.50 -95.19%	Perf Year	-90.60%
Cash/sh	9.51	P/FCF	-	EPS past 3/5Y	37.91% 39.57%	ROIC	-147.15%	52W Low	6.00 52.75%	Perf 3Y	-98.90%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	8.47% 8.91%	Perf 5Y	-99.15%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-75.54%	Oper. Margin	-	ATR (14)	0.89	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	5.01	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	36.60	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	5.01	EPS Q/Q	57.49%	SMA20	-19.45%	Beta	1.38	Target Price	150.00
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	-15.76%	Rel Volume	0.46	Prev Close	9.74
Employees	17	LT Debt/Eq	0.00	Earnings	Oct 15 BMO	SMA200	-63.18%	Avg Volume	78.84K	Price	9.16
IPO	Oct 28, 2010	Option/Short	No / Yes	EPS/Sales Surpr.	6.82% -	Trades		Volume	36,565	Change	-5.90%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-14-22	Initiated	H.C. Wainwright	Buy	$25

Nov-07-25 07:30AM	BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+ at SITC 2025 (GlobeNewswire) +15.06%
Nov-04-25 07:30AM	BriaCell to Present Robust Anti-Cancer Activity of Bria-OTS+ in Breast and Prostate Cancer Models (GlobeNewswire)
Oct-28-25 04:01AM	Zacks.com featured highlights include Groupon, BriaCell Therapeutics and InnovAge Holding (Zacks)
Oct-27-25 03:05PM	Top 3 Earnings Acceleration Buys for November (Zacks)
Oct-22-25 07:30AM	BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer (GlobeNewswire) -5.64%
07:50AM	Loading…
Oct-21-25 07:50AM	BriaCell Adds Key Clinical Sites in Phase 3 Metastatic Breast Cancer Study (GlobeNewswire) +5.19%
07:30AM	BriaCell Announces Collaboration with MSK Accelerator to Advance Bria-OTS+ for Breast Cancer (GlobeNewswire)
Oct-20-25 07:30AM	BriaCell Presents Phase 3 Clinical Biomarker Data at ESMO 2025 (GlobeNewswire)
Oct-13-25 07:30AM	BriaCell to Present Positive Clinical Biomarker Data of Phase 3 Study at ESMO 2025 (GlobeNewswire) -8.99%
Oct-03-25 07:30AM	BriaCell to Present Bria-OTS+ Preclinical Data at SITC 2025 Annual Meeting (GlobeNewswire)
Sep-12-25 12:00PM	All You Need to Know About BRIACELL THERAP (BCTX) Rating Upgrade to Buy (Zacks)
Aug-26-25 07:30AM	BriaCell's Bria-OTS+ Mechanism of Action Validated in Highly Rated Peer Reviewed Cancer Journal (GlobeNewswire) +9.61%
Aug-25-25 07:30AM	BriaCell Awarded $2 Million NCI Grant to Advance Bria-PROS+ in Prostate Cancer (GlobeNewswire) +7.32%
Aug-21-25 12:00PM	BriaCell Announces Proposed Effective Date of Share Consolidation (GlobeNewswire) -5.13%
Aug-13-25 07:30AM	BriaCell Selected for MSK's 2025 Therapeutics Accelerator Program for Bria-OTS+ for Cancer (GlobeNewswire)
08:17PM	Loading…
Aug-05-25 08:17PM	BriaCell Announces Proposed Effective Date of Share Consolidation (GlobeNewswire) -19.00%
Jul-31-25 07:30AM	BriaCell Adds UCLA Health as Key Site in Pivotal Phase 3 Breast Cancer Study (GlobeNewswire) -7.15%
Jul-30-25 07:30AM	BriaCell Awarded New Zealand Patent for its Whole Cell Technology (GlobeNewswire)
Jul-29-25 07:30AM	BriaCell's Subsidiary, BriaPro, Files Patent Application for Immuno-Oncology Platform with Novel Multitargeting Agents (GlobeNewswire)
Jul-25-25 07:30AM	BriaCell Announces Two Clinical Data Poster Presentations at ESMO 2025 (GlobeNewswire)
Jul-16-25 04:05PM	BriaCell Therapeutics Announces Closing of $15 million Public Offering (GlobeNewswire) +6.49%
Jul-15-25 03:40PM	Canadian Investment Regulatory Organization Trade Resumption - BCT (PR Newswire) -61.78%
03:30PM	Canadian Investment Regulatory Organization Trading Halt - BCT (PR Newswire)
03:05PM	BriaCell Therapeutics Announces Pricing of $15 million Public Offering (GlobeNewswire)
07:30AM	BriaCell Adds Mayo Clinic to Phase 3 Study in Metastatic Breast Cancer (GlobeNewswire)
Jul-11-25 07:30AM	BriaCell's Bria-IMT Demonstrates Survival Advantage over Trodelvy and Control Group in Metastatic Breast Cancer (GlobeNewswire)
Jul-10-25 07:30AM	BriaCell Reports Complete and Sustained Resolution of Brain Metastasis and Sustained Regression of Orbital Metastasis in "Eye-Bulging" Breast Cancer Patient (GlobeNewswire)
Jul-09-25 07:30AM	BriaCell Patient Achieves Sustained Complete Resolution of Lung Metastasis in Bria-OTS Metastatic Breast Cancer Study (GlobeNewswire) -27.49%
Jul-08-25 07:30AM	BriaCell Phase 2 Survival Achievement: 52% of Patients Surpass One-Year Milestone in Metastatic Breast Cancer (GlobeNewswire)
Jul-02-25 07:30AM	BriaCell Highlights Additional Phase 3 Clinical Sites Including Los Angeles Cancer Network and Smilow Cancer Hospital at Yale New Haven (GlobeNewswire)
07:30AM	Loading…
Jun-24-25 07:30AM	BriaCell Announces Positive Recommendation from Data Safety Monitoring Board for Pivotal Phase 3 Study in Metastatic Breast Cancer (GlobeNewswire)
Jun-04-25 07:30AM	BriaCell Announces Virtual Investor Presentations on Thursday, June 12 and Thursday, June 26 (GlobeNewswire)
Jun-02-25 07:30AM	BriaCell Reports Robust Overall Survival and Clinical Benefit Data at ASCO 2025 (GlobeNewswire)
May-27-25 07:30AM	BriaCell Bria-OTS Phase 1/2 Study Clears Safety Evaluation; Doses First Patient in Combination with Checkpoint Inhibitor (GlobeNewswire)
May-23-25 07:30AM	BriaCell Abstracts Showcase Positive Survival and Clinical Benefit Data at ASCO 2025 (GlobeNewswire) -9.97%
May-20-25 07:30AM	BriaCell CEO Letter to Shareholders (GlobeNewswire) +11.25%
May-01-25 11:04AM	New Cancer Treatments Spark Hope as Traditional Funding Faces Uncertainty (PR Newswire) -8.07%
Apr-30-25 07:30AM	BriaCell Reports Late-Breaker Phase 3 Data at AACR 2025: Positive Tolerability Profile and Potential Response Biomarkers Identified (GlobeNewswire)
Apr-28-25 04:05PM	BriaCell Therapeutics Announces Closing of $13.8 million Public Offering (GlobeNewswire) -8.20%
07:30AM	BriaCell Presents Benchmark Beating Survival and Clinical Benefit at AACR 2025; Advancements in Next Generation Bria-OTS+ Development (GlobeNewswire)
Apr-24-25 08:00PM	BriaCell Therapeutics Announces Pricing of $13.8 million Public Offering (GlobeNewswire) +11.05% -13.76%
07:30AM	BriaCell Confirms 100% Resolution of Lung Metastasis with Bria-OTS (GlobeNewswire)
Apr-23-25 07:30AM	BriaCell Announces Four Clinical Data Presentations at ASCO 2025 (GlobeNewswire)
Apr-22-25 07:30AM	BriaCell Enrollment Pace Accelerating in Phase 3 Clinical Study in Advanced Metastatic Breast Cancer (Bria-ABC) (GlobeNewswire) +27.68%
Apr-16-25 07:30AM	BriaCell Phase 2 Survival Data Beats Leading Standard in HR+ Breast Cancer (GlobeNewswire) +19.47%
Apr-10-25 08:00AM	BriaCell's Subsidiary, BriaPro, Develops Novel Antibodies to Anti-Cancer Target B7-H3 (GlobeNewswire)
Mar-26-25 08:00AM	BriaCell to Present Clinical and Preclinical Data at the 2025 AACR Conference (GlobeNewswire)
Mar-20-25 08:00AM	Second Data Safety Monitoring Board Issues Positive Recommendation to Continue BriaCell's Phase 3 Study in Metastatic Breast Cancer (GlobeNewswire)
Feb-05-25 06:15PM	BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting (GlobeNewswire) +9.27% -9.60%
04:05PM	BriaCell Therapeutics Announces Closing of Public Offering (GlobeNewswire)
Feb-03-25 07:59PM	BriaCell Therapeutics Announces Pricing of Public Offering (GlobeNewswire) -18.65%
04:45PM	BriaCell Therapeutics Announces Proposed Public Offering of Common Shares (GlobeNewswire)
07:30AM	BriaCell Announces Resolution of Lung Metastasis in First Patient treated with Bria-OTS (GlobeNewswire)
Jan-27-25 06:42PM	BriaCell Announces Completion of 15:1 Share Consolidation (GlobeNewswire)
Jan-03-25 05:05PM	BriaCell Announces Rescheduling of its Annual General Meeting of Shareholders to February 5, 2025 (GlobeNewswire) +10.47% -28.55%
05:05PM	BriaCell Announces Proposed Effective Date of Share Consolidation (GlobeNewswire)
Dec-17-24 04:05PM	BriaPro Therapeutics Corp. Announces Availability of Annual General Meeting Materials and Alternative Voting Procedures (GlobeNewswire) +6.17%
04:05PM	BriaCell Announces Availability of Annual General Meeting Materials and Alternative Voting Procedures (GlobeNewswire)
Dec-13-24 04:05PM	BriaCell Therapeutics Announces Closing of $5.5 Million Public Offering (GlobeNewswire) -7.86%
07:50AM	BriaCell 2024 SABCS Poster Highlights Ability of Bria-IMT Regimen to Increase Cancer-Fighting Immune Cells in Metastatic Breast Cancer (GlobeNewswire)
Dec-11-24 11:54PM	BriaCell Therapeutics Announces Pricing of $5.5 Million Public Offering (GlobeNewswire) -39.89%
04:05PM	BriaCell Therapeutics Announces Proposed Public Offering (GlobeNewswire)
07:50AM	BriaCell Presents Unprecedented Overall Survival Data in Metastatic Breast Cancer in Spotlight Poster at 2024 SABCS (GlobeNewswire)
Dec-02-24 10:18AM	Biotech Advances Drive Cancer Research as Global Rates Continue Upward Trend (PR Newswire) +12.99%
07:50AM	BriaCell Receives Green-Light from Data Safety Monitoring Board for its Phase 3 Study in Metastatic Breast Cancer (GlobeNewswire)
Nov-26-24 07:50AM	BriaCell 2024 SABCS Spotlight Poster to Showcase Positive Overall Survival Data Across All Patient Subtypes in Metastatic Breast Cancer (GlobeNewswire) +9.71%
Nov-25-24 07:50AM	BriaCell Provides Update to its Board of Directors (GlobeNewswire) -6.67%
Nov-21-24 07:50AM	BriaCell Announces First Patient Dosed with Bria-OTS in Metastatic Breast Cancer Study (GlobeNewswire) +31.00%
Nov-08-24 07:50AM	BriaCell Showcases Robust Anti-Cancer Activity of Personalized Off-the-Shelf Immunotherapy Pipeline at the 2024 SITC Conference (GlobeNewswire)
Nov-04-24 07:50AM	BriaCell Overall Survival Data Selected for Spotlight Poster at 2024 San Antonio Breast Cancer Symposium , December 10 13 (GlobeNewswire)
Oct-22-24 07:50AM	BriaCell Reports Outperforming Metastatic Breast Cancer Patients and Standard-Beating Survival Data (GlobeNewswire) +9.55%
Oct-15-24 07:50AM	BriaCell Provides Phase 3 Clinical Engagement Update in Metastatic Breast Cancer Pivotal Study (GlobeNewswire)
Oct-02-24 04:05PM	BriaCell Therapeutics Announces Closing of $5 Million Offering (GlobeNewswire) +24.69%
Oct-01-24 02:05PM	BriaCell Therapeutics Announces $5 Million Offering (GlobeNewswire) -34.68%
07:50AM	BriaCell Reports 100% Resolution of Brain Metastasis in Breast Cancer Patient with "Eye-Bulging" Tumor (GlobeNewswire)
Sep-18-24 07:50AM	BriaCell Announces FDA-Authorized Expanded Access Policy for Metastatic Breast Cancer Patients (GlobeNewswire) +11.34%
Sep-12-24 04:05PM	BriaCell Therapeutics Announces Closing of $8.5 Million Offering (GlobeNewswire) -11.03%
Sep-11-24 12:09PM	BriaCell Therapeutics Announces $8.5 Million Offering (GlobeNewswire)
07:50AM	BriaCell Reports Positive Overall Survival (OS) in Metastatic Breast Cancer (GlobeNewswire)
Sep-10-24 07:50AM	BriaCell Announces Positive Pre-IND Meeting with FDA for Bria-PROS+ for Prostate Cancer (GlobeNewswire) -8.90%
Sep-09-24 07:50AM	BriaCell Announces Presentation at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting (GlobeNewswire) -6.72%
Jul-18-24 07:56AM	BriaCell Quadruples Progression Free Survival (PFS) in Patient with Eye-Bulging Metastatic Breast Cancer (GlobeNewswire) -17.49%
Jun-14-24 09:52PM	BCTX Stock Earnings: BriaCell Therapeutics Beats EPS for Q3 2024 (InvestorPlace)
Jun-03-24 08:00AM	BriaCell Presents Clinical Efficacy Data at ASCO 2024 (GlobeNewswire) -9.47%
May-30-24 08:00AM	BriaCell Initiates Patient Enrollment in First-in-Human Study of Bria-OTS in Advanced Metastatic Breast Cancer (GlobeNewswire)
May-28-24 08:00AM	BriaCell Announces Clinical Supply Agreement with BeiGene for Bria-OTS First in Human Study (GlobeNewswire)
07:27AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace)
May-24-24 08:00AM	BriaCell Doubles Progression-Free-Survival (PFS) and Reports Clinical Benefit Data at ASCO 2024 (GlobeNewswire)
May-21-24 07:39AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace)
May-17-24 04:33PM	BriaCell Therapeutics Announces Closing of $5.0 Million Registered Direct Offering (GlobeNewswire) +7.19%
May-15-24 08:00AM	BriaCell Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering (GlobeNewswire) -22.75%
Apr-24-24 08:00AM	BriaCell Announces Oral and Poster Presentations at ASCO 2024 (GlobeNewswire) -5.60%
Apr-10-24 08:00AM	BriaCell 2024 AACR Preclinical Poster Confirms Strong Anti-Cancer Activity of Bria-OTS+ and Bria-PROS+ Clinical Candidates for Breast and Prostate Cancer (GlobeNewswire)
Apr-09-24 08:00AM	BriaCell Showcases Data Demonstrating Unmatched Progression-Free Survival (PFS) and Clinical Efficacy in Antibody-Drug Conjugate (ADC) Resistant and Central Nervous System (CNS) Metastatic Breast Cancer at the 2024 AACR (GlobeNewswire)
Mar-19-24 06:52AM	BCTX Stock Earnings: BriaCell Therapeutics Reported Results for Q2 2024 (InvestorPlace) -6.55%
Mar-07-24 08:00AM	BriaCell Receives and Executes Letter of Intent to Advance Clinical Development of Breast and Prostate Cancer Immunotherapies (GlobeNewswire) -7.05%
Mar-06-24 08:00AM	BriaCell to Present Clinical Data in Central Nervous System (CNS) Metastasis and Antibody-Drug Conjugate (ADC) Resistant Breast Cancer at the 2024 AACR Conference (GlobeNewswire) -8.24%
Feb-27-24 08:00AM	BriaCell Provides Update on Alleged Illegal Trading of Public Securities (GlobeNewswire)
Feb-07-24 08:00AM	BriaCell Announces Strong Clinical Data in Breast Cancer Patients; Reports Another Notable Responder Case (GlobeNewswire)
Feb-06-24 08:30AM	Breaking Ground in Prostate Cancer: BriaCell Announces Lead Prostate Cancer Candidate Bria-Pros+, Initiates GMP Manufacturing (GlobeNewswire) +5.34%

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company, which engages in the development of novel immunotherapies to transform cancer care. It currently advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor in a pivotal 1 Phase 3 study in metastatic breast cancer. The company was founded by Charles L. Wiseman and Isaac Benjamin Maresky on July 26, 2006 and is headquartered in West Vancouver, Canada.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BCTX

BriaCell Therapeutics Corp

Upgrade your FINVIZ experience